

Abstract of the Disclosure

A treatment process is disclosed that
5 comprises administering an effective amount of an
aromatic sulfone hydroxamic acid that exhibits
excellent inhibitory activity of one or more matrix
metalloprotease (MMP) enzymes, such as MMP-2, MMP-9
and MMP-13, while exhibiting substantially less
10 inhibition at least of MMP-1 to a host having a
condition associated with pathological matrix
metalloprotease activity. Also disclosed are
metalloprotease inhibitor compounds having those
selective activities, processes for manufacture of
15 such compounds and pharmaceutical compositions using
an inhibitor. A contemplated compound corresponds in
structure to formula B, below,

